Atherothrombosis, inflammation, and diabetes

Journal of the American College of Cardiology

Volumn 41, Issue 7, 2003, Pages 1071-1077

  Biondi Zoccai, Giuseppe G L ^a   Abbate, Antonio ^a   Liuzzo, Giovanna ^a   Biasucci, Luigi M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; FENOFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THROMBOCYTE FACTOR 4; TROGLITAZONE; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERINSULINEMIA; INSULIN RESISTANCE; OBESITY; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RISK ASSESSMENT; THROMBOSIS;

EID: 0037414074     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00088-3     Document Type: Article

References (61)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035-8.
2. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 1998;21:1138-45.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
4. Marso SP. Optimizing the diabetic formulary: beyond aspirin and insulin. J Am Coll Cardiol 2002;40:652-61.
5. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
6. Dortimer AC, Shenoy PN, Shiroff RA, et al. Diffuse coronary artery disease in diabetic patients: fact or fiction? Circulation 1978;57:133-6.
7. Davies MJ. The pathological basis of angina pectoris. Cardiovasc Drugs Ther 1989;3 Suppl 1:249-55.
8. Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;102:2180-4.
9. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPAR-gamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402: 880-3.
10. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPAR-alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125-31.
11. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR-alpha but not by PPAR-gamma activators. Nature 1998;393:790-3.
12. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000;101:235-8.
13. Aljada A, Garg R, Ghanim H, et al. Nuclear factor-kappa-B suppressive and inhibitor-kappa-B stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action? J Clin Endocrinol Metab 2001;86:3250-6.
14. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001;22:2243-52.
15. Syvanne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997;350 Suppl I:20-3.
16. The Heart Protection Study Collaborative Group. The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
17. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1-9.
18. Brownlee M. Negative consequences of glycation. Metabolism 2000; 49:9-13.
19. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434-8.
20. Stitt AW, Bucala R, Vlassara H. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann NY Acad Sci 1997;811:115-27.
21. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995; 1:447-56.
22. Winocour PD, Kinlough-Rathbone RL, Mustard JF. Pathways responsible for platelet hypersensitivity in rats with diabetes. II. Spontaneous diabetes in BB Wistar rats. J Lab Clin Med 1986;107:154-8.
23. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-82.
24. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991;34: 356-61.
25. Lindeman RD, Romero LJ, Hundley R, et al. Prevalences of type 2 diabetes, the insulin resistance syndrome, and coronary heart disease in an elderly, biethnic population. Diabetes Care 1998;21:959-66.
26. Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 1999;277:E971-5.
27. Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-600.
28. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:455-61.
29. Ford ES. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of U.S. adults. Am J Epidemiol 2002;155:57-64.
30. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353:1649-52.
31. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellkus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
32. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803.
33. The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
34. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-8.
35. Peng HB, Rajavashisth TB, Libby P, Liao JK. Nitric oxide inhibits macrophage colony-stimulating factor gene transcription in vascular endothelial cells. J Biol Chem 1995;270:17050-5.
36. Kroder G, Bossenmaier B, Kellerer M, et al. Tumor necrosis factor-alpha and hyperglycemia-induced insulin resistance. J Clin Invest 1996;97:1471-77.
37. Jager A, van Hinsbergh VW, Kostense PJ, et al. Increased levels of soluble vascular cell adhesion molecule-1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes 2000;49:485-91.
38. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-14.
39. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338-42.
40. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
41. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
42. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-6.
43. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997;96:4095-103.
44. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999;99:1560-6.
45. Blackburn R, Giral P, Bruckert E, et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol 2001;21:1962-8.
46. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction - a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
47. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60.
48. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584-90.
49. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, the FRagmin during InStability in Coronary artery disease (FRISC) Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139-47.
50. Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999;100:1958-63.
51. Biasucci LM, Liuzzo G, Angiolillo DJ, Biondi-Zoccai GGL, Abbate A, Crea F. C-reactive protein may have a different prognostic value in diabetics and non-diabetics with unstable angina (abstr). Eur Heart J 2002;23 Suppl:171.
52. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI)-11A substudy. J Am Coll Cardiol 1998;31:1460-5.
53. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB, the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
54. Heeschen C, Hamm CW, Bruemmer J, Simoons ML, the Chimeric 7E3 AntiPlateleT in Unstable angina REfractory to standard treatment (CAPTURE) Investigators. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. J Am Coll Cardiol 2000;35:1535-42.
55. Bhatt DL, Chew DP, Robbins MA, et al. Elevated baseline CRP levels predict death or MI in diabetic patients undergoing percutaneous coronary intervention (abstr). J Am Coll Cardiol 2001;37 Suppl:648A.
56. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-21.
57. Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002;105:1412-5.
58. Patti G, Di Sciascio G, D'Ambrosio A, Dicuonso G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol 2002;89:372-6.
59. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
60. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONItoring trends and determinants in CArdiovascular disease (MONICA) Augsburg cohort study, 1984 to 1992. Circulation 1999;99:237-42.
61. Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002;105:800-3.